Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GSK 
GlaxoSmithKline PLC ADR (GSK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
05/20/2025: GSK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Year Target Price $41.54
Year Target Price $41.54
| 1 | Strong Buy |
| 0 | Buy |
| 5 | Hold |
| 0 | Under performing |
| 2 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -8.73% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 05/20/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 78.06B USD | Price to earnings Ratio 18.55 | 1Y Target Price 41.54 |
Price to earnings Ratio 18.55 | 1Y Target Price 41.54 | ||
Volume (30-day avg) - | Beta 0.27 | 52 Weeks Range 31.01 - 43.19 | Updated Date 06/29/2025 |
52 Weeks Range 31.01 - 43.19 | Updated Date 06/29/2025 | ||
Dividends yield (FY) 4.15% | Basic EPS (TTM) 2.08 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10% | Operating Margin (TTM) 30.79% |
Management Effectiveness
Return on Assets (TTM) 6.55% | Return on Equity (TTM) 27.1% |
Valuation
Trailing PE 18.55 | Forward PE 8.58 | Enterprise Value 97192820197 | Price to Sales(TTM) 2.48 |
Enterprise Value 97192820197 | Price to Sales(TTM) 2.48 | ||
Enterprise Value to Revenue 2.25 | Enterprise Value to EBITDA 9.21 | Shares Outstanding 2023270016 | Shares Floating 3947163260 |
Shares Outstanding 2023270016 | Shares Floating 3947163260 | ||
Percent Insiders 0.06 | Percent Institutions 18.34 |
Analyst Ratings
Rating 2.88 | Target Price 41.54 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 5 | Sell 1 | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
GlaxoSmithKline PLC ADR
Company Overview
History and Background
GlaxoSmithKline PLC (GSK) was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham. Its roots trace back to the 18th century. It is headquartered in London, UK and has grown to become a global leader in pharmaceuticals and vaccines.
Core Business Areas
- Pharmaceuticals: Develops and manufactures prescription medicines, including specialty and general medicines, vaccines, and HIV medicines.
- Vaccines: Offers a wide range of vaccines for various diseases, including childhood vaccinations, travel vaccines, and influenza vaccines.
- Consumer Healthcare: The consumer healthcare business was previously a core area but was spun off into Haleon (HLN) in 2022.
Leadership and Structure
GSK is led by CEO Emma Walmsley. The organizational structure consists of various divisions, including pharmaceuticals, and vaccines, each headed by senior leadership. GSK operates under a board of directors responsible for overall governance.
Top Products and Market Share
Key Offerings
- Shingrix: A vaccine for shingles. Shingrix dominates the market for shingles vaccines. Competitors: Merck's Zostavax (discontinued).
- Duvroq: Daprodustat for anemia associated with chronic kidney disease. Competitors: Akebia Therapeutics' Vafseo and FibroGen's Evrenzo.
- Arexvy: Respiratory syncytial virus (RSV) vaccine. Competitors: Pfizer's Abrysvo and Moderna's mRNA-1345.
- Nucala: An anti-IL5 biologic for severe asthma and other eosinophilic conditions. Competitors: Teva Pharmaceutical Industries' Cinqaero, AstraZeneca's Fasenra.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. There is a growing demand for innovative medicines and vaccines.
Positioning
GSK is a major player in the pharmaceutical and vaccine markets, focusing on innovation and global reach. It has a strong portfolio of established products and a pipeline of promising new therapies.
Total Addressable Market (TAM)
The global pharmaceuticals market is valued at over $1.4 trillion. The vaccine market is approximately $60 billion. GSK aims to capture a significant portion of these markets through its innovative products and global presence.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Global presence and distribution network
- Diversified product portfolio
- Leading position in vaccines
- Established brand reputation
Weaknesses
- Dependence on key products
- Exposure to patent expirations
- High R&D costs
- Regulatory risks
- Litigation risks
Opportunities
- Expanding into emerging markets
- Developing innovative therapies for unmet needs
- Acquiring or partnering with biotech companies
- Leveraging digital technologies
- Increasing demand for vaccines
Threats
- Generic competition
- Pricing pressures
- Regulatory changes
- Economic downturns
- Increased competition from other pharmaceutical companies
Competitors and Market Share
Key Competitors
- PFE
- MRK
- JNJ
- NVS
- AZN
- BMY
- ABBV
Competitive Landscape
GSK's advantages include a strong vaccine portfolio and global presence. Disadvantages include reliance on key products and exposure to patent expirations. Competitors such as Pfizer and Merck have larger market caps and are very successful companies.
Major Acquisitions
Affinivax
- Year: 2022
- Acquisition Price (USD millions): 2100
- Strategic Rationale: Strengthen GSK's vaccine pipeline with next-generation pneumococcal vaccines.
Growth Trajectory and Initiatives
Historical Growth: GSK's historical growth has been influenced by product launches, acquisitions, and market conditions.
Future Projections: Analyst estimates suggest continued growth in key therapeutic areas, driven by innovative products and expanding market access.
Recent Initiatives: Recent strategic initiatives include focusing on core therapeutic areas, investing in R&D, and divesting non-core assets (e.g., the Haleon spinoff).
Summary
GSK is a major pharmaceutical and vaccine company with a global reach and a strong pipeline. It's vaccine division is a key strength, but it faces challenges from generic competition and regulatory pressures. Its recent streamlining efforts, including the Haleon spin-off, aim to focus on core businesses. GSK must continue to innovate and diversify its product portfolio to maintain its competitive edge.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
- Third-party Financial Data Providers
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GlaxoSmithKline PLC ADR
Exchange NYSE | Headquaters - | ||
IPO Launch date 1986-07-09 | CEO & Director Ms. Emma Natasha Walmsley | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 68629 | Website https://www.gsk.com |
Full time employees 68629 | Website https://www.gsk.com | ||
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.